Celcuity Inc
Celcuity Inc (CELC) Wheel Strategy
CELC wheel strategy scan found 32 cash-secured put setups on the previous trading day. Probability of expiring worthless is above 50%. Annualized returns reach up to 47.6%.
Read more
Running a CELC wheel strategy lets you generate consistent premium income on Celcuity Inc while setting your own entry and exit prices on the underlying. Celcuity Inc's wheel combines cash-secured puts and covered calls into a repeatable cycle: sell puts at strikes where you'd be happy to own CELC, and if assigned, sell calls at strikes where you'd be happy to sell. Use our scanner to find the best CELC wheel strategy setups in real time.
The wheel works best on liquid, high-quality names with stable fundamentals and active options markets — exactly the profile many large-cap leaders fit. The mechanics are simple: sell a cash-secured put on CELC, collect premium, and either keep the premium if it expires worthless or take assignment at a discount to current price. Once assigned, sell covered calls against the shares to keep collecting premium until they're called away. Choosing the right strikes, expirations, and IV environment is what separates a profitable CELC wheel from a losing one.
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer.
The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
The difference between a wheel that compounds and one that bleeds comes down to strike selection, IV timing, and discipline on assignment. Our scanner handles the heavy lifting: it ranks every leg of the CELC wheel strategy by delta, premium yield, IV rank, and days to expiration, so you can deploy capital where the math works. Build your CELC wheel strategy on data, not gut feel — and let the options wheel do what it does best: pay you to wait.
| Oct 16, 2026 | 75.00 | $1.60 | $2.25 | -0.29 | 23 | 12% | 64.8% | 47.6% | 216 |
| Nov 20, 2026 | 75.00 | $3.70 | $4.95 | -0.34 | 58 | 12% | 57.3% | 41.5% | 192 |
| Jan 15, 2027 | 75.00 | $6.50 | $8.05 | -0.35 | 114 | 12% | 52.7% | 34.4% | 111 |
| Dec 18, 2026 | 75.00 | $4.50 | $6.05 | -0.34 | 86 | 12% | 54.6% | 34.2% | 1 |
| Nov 20, 2026 | 70.00 | $1.90 | $3.10 | -0.24 | 58 | 12% | 68.4% | 27.9% | 134 |
| Oct 16, 2026 | 70.00 | $1.00 | $1.15 | -0.17 | 23 | 12% | 80.2% | 26.1% | 930 |
| Dec 18, 2026 | 70.00 | $3.20 | $4.10 | -0.26 | 86 | 12% | 63.9% | 24.9% | 4 |
| Jan 15, 2027 | 70.00 | $4.40 | $5.40 | -0.27 | 114 | 12% | 60.9% | 24.7% | 14 |
| Mar 19, 2027 | 70.00 | $6.50 | $7.90 | -0.28 | 177 | 12% | 56.6% | 23.3% | 0 |
| Jan 15, 2027 | 65.00 | $2.55 | $4.38 | -0.22 | 114 | 12% | 69.2% | 21.6% | 305 |
As of September 24, 2026
Run the Wheel on CELC With Confidence
Find the best CELC wheel strategy setups across strikes and expirations, plan ahead with at-strike values, and keep your covered calls and puts on track.
Start your 14-day free trial→